Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Trientine (A16ax12) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Ritonavir (J05ae03) as Part of a So-Called Open House Model.

Open House Drug Discount Agreements Colecalciferol, Rx, Prescription Products, Atc A11cc05

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Teriflunomide (L04aa31) as Part of a So-Called Open House Model.

Open House Drug Discount Agreements Botulinum Toxin Type A, Finished Drug Name: Xeomin(R), Atc M03ax21

Drug Discount Contracts According to § 130A Paragraph 8 Sgb V in the Context of Open House Procedures

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Contracts for Multiple Active Ingredients/Active Ingredient Combinations

Open House Original Discount Contracts 2023-01 - Dolutegravir

Open House Original Rebate Agreements 2023-02 - Lamivudine/Abacavir/Dolutegravir (Drug Combination)